Tag: Vaxxas
-
Brisbane-based biotech scores massive funding win
A biotechnology company has secured $90 million in debt and equity funding for its needle-free vaccine delivery technology. Vaxxas Pty Ltd is pioneering the high-density microarray patch (HD-MAP) to be used as an alternative to vaccination by needle. The $90 million secured for the project is one of the largest financings for an Australian biotech…
-
Brisbane company to trial needle-free Bird Flu vaccine
The trial will assess an avian flu vaccine delivered with Vaxxas’ proprietary needle-free vaccine patch, called the high-density microarray patch or HD-MAP. Comprising 258 participants aged between 18 and 50 years old from Queensland and Victoria, this trial represents Vaxxas’ largest Phase I clinical study to date. Since its establishment in 2011, the biotech company…